Dr. Bochner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
680 N Lake Shore Dr
Ste 1000
Chicago, IL 60611Phone+1 312-695-9797Fax+1 312-695-6070
Education & Training
- Johns Hopkins UniversityFellowship, Allergy and Immunology, 1985 - 1988
- University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1982 - 1985
- University of Illinois College of MedicineClass of 1982
Certifications & Licensure
- IL State Medical License 1982 - 2026
- MD State Medical License 1985 - 2018
- American Board of Allergy and Immunology Allergy & Immunology
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1999
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
- Join now to see all
Clinical Trials
- Inhibition of Anaphylaxis by Ibrutinib Start of enrollment: 2017 Apr 10
Publications & Presentations
PubMed
- 186 citationsRisk assessment in anaphylaxis: current and future approachesF. Estelle R. Simons, Anthony J. Frew, Ignacio J. Ansotegui, Bruce S. Bochner, David B.K. Golden
The Journal of Allergy and Clinical Immunology. 2007-07-01 - 14 citationsAdhesion molecules as therapeutic targets.Bruce S. Bochner
Immunology and Allergy Clinics of North America. 2004-11-01 - 35 citationsSialic acid–binding immunoglobulin-like lectin 8 (Siglec-8) is an activating receptor mediating β2-integrin–dependent function in human eosinophilsDaniela J. Carroll, Jeremy A. O'Sullivan, David B. Nix, Yun Cao, Michael Tiemeyer
The Journal of Allergy and Clinical Immunology. 2018-06-01
Press Mentions
- Scientists Say They're on Brink of Wonder Pill That Could 'Cure Most Allergies'June 5th, 2020
- New Pill Could Prevent Anaphylaxis in People with Food, Drug AllergiesJune 2nd, 2020
- Chemotherapy Drug Shows Promise in Treating Everyday AllergiesFebruary 20th, 2018
- Join now to see all
Grant Support
- Treating Lung Inflammation By Targeting SiglecsNational Heart, Lung, And Blood Institute2011
- Basic And Clinical ImmunologyNational Institute Of Allergy And Infectious Diseases2008–2011
- Targeting Siglec-8/Siglec-F Reduce Allergic Responses In Vitro And In VivoNational Institute Of Allergy And Infectious Diseases2007–2011
- Determination Of Cellular And Clinical Thresholds For Ige-Mediated ReactivityNational Institute Of Allergy And Infectious Diseases2007–2010
- Adhesion Molecule Biology In Allergic CellsNational Institute Of Allergy And Infectious Diseases2003–2007
- Cellular And Clinical Thresholds For Ige-Mediated ReactiNational Institute Of Allergy And Infectious Diseases2006
- Tissue-Specific Mechanisms Of Allergic InflammationNational Institute Of Allergy And Infectious Diseases2001–2004
- Adhesion Molecule Biology In Allergic CellsNational Institute Of Allergy And Infectious Diseases2003
- Glycolipid E-Selectin Ligands On Human GranulocytesNational Institute Of Allergy And Infectious Diseases2000–2003
- Role Of TNF Alpha In Allergic LATE Phase ResponseNational Institute Of Allergy And Infectious Diseases2001–2002
- Integrins And Chemokines In Allergic Cell RecruitmentNational Institute Of Allergy And Infectious Diseases1998–2002
- Integrins And Chemokines In Allergic Cell RecruitmentNational Institute Of Allergy And Infectious Diseases1997
- Cellular Recruitment Mechanisms In Allergic InflammationNational Heart, Lung, And Blood Institute1996–1997
- Basophil Activation And Recruitment In Allergic DiseaseNational Institute Of Allergy And Infectious Diseases1993
- Basophil Activation And Recruitment In Allgergic DiseaseNational Institute Of Allergy And Infectious Diseases1989–1992
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: